Reply to the letter to the editor 'Anti-EGFR therapy in oesophagogastric cancer: precise but not enough' by M. Salati and S. Cascinu

Ann Oncol. 2018 Sep 1;29(9):2018. doi: 10.1093/annonc/mdy238.

Authors

T Ruhstaller¹, R Langer², P Thuss-Patience³, W Eisterer⁴, M Stahl⁵

Affiliations

¹ Department of Oncology and Haematology, Cantonal Hospital of St. Gallen, St. Gallen.
² Institute of Pathology, University Hospital of Berne, Berne, Switzerland.
³ Department of Haematology, Oncology and Tumorimmunology, University Medicine, Berlin, Germany.
⁴ Medical Department, Medical University, Innsbruck, Austria.
⁵ Medical Oncology, Kliniken Essen-Mitte, Essen, Germany.

PMID: 29992287
DOI: 10.1093/annonc/mdy238

No abstract available

Publication types

Letter
Comment

MeSH terms

Cetuximab
Chemoradiotherapy
ErbB Receptors
Esophageal Neoplasms*
Humans
Neoadjuvant Therapy*

Substances

EGFR protein, human
ErbB Receptors
Cetuximab